Home > Pharma > The difficulty of treating hepatitis C

The difficulty of treating hepatitis C

July 22nd, 2010

By jeremy.engdahl-johnson

The New York Times considers the long-term implications of hepatitis C and the efforts to treat it with drugs that are now becoming available. Here is an excerpt:

But even if the [hepatitis C] drugs do work, some experts and doctors warn that this virus may be particularly tough to vanquish. Three-quarters of the people who are infected do not know it because they are not tested for the virus and because the infection can be asymptomatic for years while it stealthily attacks the liver.

And because this disease is transmitted by blood, those infected largely are former or current IV-drug users — a population that characteristically has little or no health insurance — who may not be the most able to stick to a lengthy treatment regimen that can cause brutal side effects…

Vertex has commissioned studies projecting a rising toll from hepatitis C. One such study, done by Milliman, a health insurance consulting firm, projected that the number of people with advanced liver disease from hepatitis C would quadruple in 20 years if treatment did not improve.

The Milliman report is available here.

Pharma ,

  1. August 10th, 2012 at 08:52 | #1

    As a Neurological Learning Facilitator for THE LEARNING CLINIC WORLDWIDE, I obviously do not understand the complexities involved in the treatment of Hepatitis C. However, it would appear that the nanozymes developed by Chemist Y. Charles Cao and pathologist Chen Liu at the University of Florida hold great promise for effective treatment without the highly toxic side effects of earlier drugs targeting Hepatitis C. – J. Collins Meek, Ph.D., docmeek.com

  1. No trackbacks yet.